We aimed to evaluate the change in bone mineral density (BMD) in patients with prostate
cancer (PCa) receiving androgen deprivation therapy (ADT) compared to those with PCa or …

Androgen-deprivation therapy (ADT) has become a standard of care in the management of
advanced prostate cancer or as an adjunct therapy. However, ADT is associated with a well …

To test the efficacy and safety of leuprolide acetate (Lupron Depot®) in the treatment of
Alzheimer's disease (AD), we conducted a 48-week, double-blind, placebo-controlled, dose …

The prevalence of osteoporosis in men with prostate cancer (PCa) on androgen deprivation
therapy (ADT) is well documented, with up to 53% affected by this bone condition. However …

Objectives To investigate the risk of thromboembolic disease (TED) in men with prostate
cancer (PC a) on androgen deprivation therapy (ADT), while accounting for known TED risk …

Simple Summary More than 50% of prostate cancer patients will receive androgen
deprivation therapy (ADT) and 70% will experience ADT-induced weight gain. Supervised …

Background and Objective: Prostate cancer is the most prevalent non-cutaneous cancer in
men, which causes significant mortality among the patients. Since prostate cancer cells are …

Androgen deprivation therapy (ADT) is now considered a mainstay in the treatment of
metastatic and locally advanced prostate cancer (PCa). Despite well-established benefits of …

Prostate cancer and treatment with androgen deprivation therapy (ADT) affect significant
numbers of the male population. Endocrine effects of ADT are a critical consideration in …

The aim of this study was to provide a specific review of current medical literature regarding
the lipid profile during prostate carcinoma (PCa) treatment. The main aim was to analyze the …